Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

An announcement from AstraZeneca ( ($GB:AZN) ) is now available. AstraZeneca announced that its CEO, Pascal Soriot, has gifted 136,537 ordinary ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 ...

AstraZeneca ( AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K.

AstraZeneca was among the first multinational pharmaceutical firms to invest deeply in China's healthcare sector. Through ...

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.